Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/thoraxjnl-2020-215383 http://scihub22266oqcxt.onion/10.1136/thoraxjnl-2020-215383 33622981!ä!33622981 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Thorax 2021 ; 76 (10): 970-979 Nephropedia Template TP {{tp|p=33622981|t=2021. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis |pdf=|usr=}}{{33622981}} gab.com Text Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis JO: Thorax http://www.kidney.de/pget.php?&tw=1&pmid=33622981 #FOAvip BACKGROUND: The prevalence of venous thromboembolic event (VTE) and arterial thromboembolic event (ATE) thromboembolic events in patients with COVID-19 remains largely unknown. METHODS: In this meta-analysis, we systematically searched for observational studies describing the prevalence of VTE and ATE in COVID-19 up to 30 September 2020. RESULTS: We analysed findings from 102 studies (64 503 patients). The frequency of COVID-19-related VTE was 14.7% (95% CI 12.1% to 17.6%, I(2)=94%; 56 studies; 16 507 patients). The overall prevalence rates of pulmonary embolism (PE) and leg deep vein thrombosis were 7.8% (95% CI 6.2% to 9.4%, I(2)=94%; 66 studies; 23 117 patients) and 11.2% (95% CI 8.4% to 14.3%, I(2)=95%; 48 studies; 13 824 patients), respectively. Few were isolated subsegmental PE. The VTE prevalence was significantly higher in intensive care unit (ICU) (23.2%, 95% CI 17.5% to 29.6%, I(2)=92%, vs 9.0%, 95% CI 6.9% to 11.4%, I(2)=95%; p(interaction)<0.0001) and in series systematically screening patients compared with series testing symptomatic patients (25.2% vs 12.7%, p(interaction)=0.04). The frequency rates of overall ATE, acute coronary syndrome, stroke and other ATE were 3.9% (95% CI 2.0% to to 3.0%, I(2)=96%; 16 studies; 7939 patients), 1.6% (95% CI 1.0% to 2.2%, I(2)=93%; 27 studies; 40 597 patients) and 0.9% (95% CI 0.5% to 1.5%, I(2)=84%; 17 studies; 20 139 patients), respectively. Metaregression and subgroup analyses failed to explain heterogeneity of overall ATE. High heterogeneity limited the value of estimates. CONCLUSIONS: Patients admitted in the ICU for severe COVID-19 had a high risk of VTE. Conversely, further studies are needed to determine the specific effects of COVID-19 on the risk of ATE or VTE in less severe forms of the disease. Twit Text FOAVip Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis ????Thorax http://www.kidney.de/pget.php?&tw=1&pmid=33622981 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33622981 #FOAvip English Wikipedia <ref>{{Cite pmid|33622981}}</ref> Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis #MMPMID33622981 Tan BK; Mainbourg S; Friggeri A; Bertoletti L; Douplat M; Dargaud Y; Grange C; Lobbes H; Provencher S; Lega JC Thorax 2021[Oct]; 76 (10): 970-979 PMID33622981show ga BACKGROUND: The prevalence of venous thromboembolic event (VTE) and arterial thromboembolic event (ATE) thromboembolic events in patients with COVID-19 remains largely unknown. METHODS: In this meta-analysis, we systematically searched for observational studies describing the prevalence of VTE and ATE in COVID-19 up to 30 September 2020. RESULTS: We analysed findings from 102 studies (64 503 patients). The frequency of COVID-19-related VTE was 14.7% (95% CI 12.1% to 17.6%, I(2)=94%; 56 studies; 16 507 patients). The overall prevalence rates of pulmonary embolism (PE) and leg deep vein thrombosis were 7.8% (95% CI 6.2% to 9.4%, I(2)=94%; 66 studies; 23 117 patients) and 11.2% (95% CI 8.4% to 14.3%, I(2)=95%; 48 studies; 13 824 patients), respectively. Few were isolated subsegmental PE. The VTE prevalence was significantly higher in intensive care unit (ICU) (23.2%, 95% CI 17.5% to 29.6%, I(2)=92%, vs 9.0%, 95% CI 6.9% to 11.4%, I(2)=95%; p(interaction)<0.0001) and in series systematically screening patients compared with series testing symptomatic patients (25.2% vs 12.7%, p(interaction)=0.04). The frequency rates of overall ATE, acute coronary syndrome, stroke and other ATE were 3.9% (95% CI 2.0% to to 3.0%, I(2)=96%; 16 studies; 7939 patients), 1.6% (95% CI 1.0% to 2.2%, I(2)=93%; 27 studies; 40 597 patients) and 0.9% (95% CI 0.5% to 1.5%, I(2)=84%; 17 studies; 20 139 patients), respectively. Metaregression and subgroup analyses failed to explain heterogeneity of overall ATE. High heterogeneity limited the value of estimates. CONCLUSIONS: Patients admitted in the ICU for severe COVID-19 had a high risk of VTE. Conversely, further studies are needed to determine the specific effects of COVID-19 on the risk of ATE or VTE in less severe forms of the disease. |COVID-19/*complications/diagnosis/therapy[MESH] |Critical Care[MESH] |Hospitalization[MESH] |Humans[MESH] |Prevalence[MESH]Arterial and venous thromboembolism in COVID-19: a study-level meta-an(epmc).pdf DeepDyve Pubget Overpricing